ReviewFibroblast growth factor-23 and Klotho in chronic kidney disease
Keywords
Cited by (0)
This issue was organized by the VDR Expert Centers and was funded by Abbott Laboratories with a collaborative effort to advance and support the science and the improvement of quality of life for renal patients. MGV has received consulting fees from or participated in paid advisory boards for Amgen, Abbott Laboratories, and Fresenius; received lecture fees for speaking at the invitation of Abbott Laboratories and Amgen; and received grant support from Genzyme and Shire. TEL has received consulting fees from or participated in paid advisory boards for Genzyme, Abbott Laboratories, and Swedish-Orphan, and has received lecture fees for speaking at the invitation of Amgen, AstraZeneca, Shire, Genzyme, and Abbott Laboratories.
TO CITE THIS ARTICLE: Vervloet MG, Larsson TE. Fibroblast growth factor-23 and Klotho in chronic kidney disease. Kidney inter., Suppl. 2011; 1: 130–135.